कृपया अन्य खोज का प्रयास करें
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Leonard Kruimer | 63 | 2018 | Independent Chairman of the Board |
Kristoffer Bissessar | 54 | 2020 | Independent Director |
Thomas O. Hecht | 71 | 2020 | Independent Director |
Rienk Offringa | - | 2017 | Member of Scientific Advisory Board |
Alexander Rudensky | - | 2017 | Member of Scientific Advisory Board |
Bernd Robert Seizinger | 68 | 2018 | Independent Director |
Erik Esveld | 54 | 2023 | Director |
Vessela Alexieva | 65 | - | Employee Representative Director |
Stephen Beers | - | - | Member of Scientific Advisory Board |
Vincent Ossipow | 56 | 2021 | Independent Director |
Martin Palsson | 45 | 2022 | Employee Representative Director |
Natalie Brittenham Berner | 34 | 2022 | Independent Director |
Falk Nimmerjahn | - | 2017 | Member of Scientific Advisory Board |
Mark Cragg | - | - | Member of Scientific Advisory Board |
Alexander Maximiliaan Marie Eggermont | - | 2021 | Member of Scientific Advisory Board |
Nanna Luneborg | 48 | 2022 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है